Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...

A federal judge just invoked Star Trek in a $5 billion patent ruling against Moderna. Here is why the mRNA giant is heading ...

Moderna faces a $5b patent infringement lawsuit over its COVID-19 vaccine, now moving to trial after a key court ruling. The company is also appointing Dr. David Berman as Chief Development Officer, ...

Moderna has out-licensed a rare disease drug candidate to Recordati, accepting $50 million upfront for an asset that could ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans to pull away from late-stage clinical trial investments in the area.

Moderna (MRNA) is back in focus after pairing a new rare disease collaboration on mRNA-3927 with Recordati with a leadership ...

Moderna Inc.’s chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of growing opposition to immunizations from US officials.

Wall Street expects a year-over-year decline in earnings on lower revenues when Moderna (MRNA) reports results for the ...

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update revealing the long‑term results from a cancer therapy study.

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin cancer after five years, new data confirming its prolonged benefit show.

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b trial showed.